Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2016 Jul 6.
Published in final edited form as: Inorg Chem. 2015 Jun 12;54(13):6281–6290. doi: 10.1021/acs.inorgchem.5b00584

Structure and Properties of fac-[ReI(CO)3(NTA)]2− (NTA3− = Tri-anion of Nitrilotriacetic Acid) and fac-[ReI(CO)3(L)]n− Analogs Useful for Assessing the Excellent Renal Clearance of the fac-[99mTcI(CO)3(NTA)]2− Diagnostic Renal Agent

Jeffrey Klenc †,*, Malgorzata Lipowska , Pramuditha L Abhayawardhana , Andrew T Taylor , Luigi G Marzilli ‡,*
PMCID: PMC4863976  NIHMSID: NIHMS783725  PMID: 26068141

Abstract

We previously identified two new agents based on the [99mTcVO]3+ core with renal clearances in human volunteers 30% higher than that of the widely used clinical tracer 99mTc-MAG3 (MAG35− = penta-anion of mercaptoacetyltriglycine). However, renal agents with even higher clearances are needed. More recently, we changed our focus from the [99mTcVO]3+ core to the discovery of superior tracers based on the fac-[99mTcI(CO)3]+ core. Compared to 99mTc-MAG3, fac-[99mTcI(CO)3(NTA)]2− (NTA3− = tri-anion of nitrilotriacetic acid) holds great promise by virtue of its efficient renal clearance via tubular secretion and the absence of hepatobiliary elimination, even in patients with severely reduced renal function. We report here NMR, molecular (X-ray) structure, and solution data on fac-[ReI(CO)3(NTA)]2− with a –CH2CO2 dangling monoanionic chain and on two fac-[ReI(CO)3(L)] analogs with either a –CH2CONH2 or –CH2CH2OH dangling neutral chain. In these three fac-[ReI(CO)3(L)]n− complexes, the fac-[ReI(CO)3(N(CH2CO2)2)] moiety is structurally similar and has similar electronic properties (as assessed by NMR data). In reported and ongoing studies, the two fac-[99mTcI(CO)3(L)] analogs with these neutral dangling chains were found to have pharmacokinetic properties very closely similar to those of fac-[99mTcI(CO)3(NTA)]2−. Therefore, we reach the unexpected conclusion that in fac-[99mTcI(CO)3(L)]n− agents, renal clearance is affected much more than anticipated by features of the core plus the chelate rings (the [99mTcI(CO)3(N(CH2CO2)2)] moiety) than by the presence of a negatively charged dangling carboxylate chain.

TOC Image

graphic file with name nihms783725u1.jpg

INTRODUCTION

99mTc radiopharmaceuticals are widely employed in nuclear medicine for imaging and for assessing physiological function and disease. The close relation between Tc and Re chemistry has led to the use of the Re/99mTc strategy of synthesizing and characterizing Re complexes and performing animal biodistribution studies with the 99mTc analogs. Renal 99mTc radiopharmaceuticals are used to image the kidney, evaluate suspected renal disease, and monitor renal function. Image quality is dependent on rapid removal of the radiotracer from the circulating plasma by the kidney; the rate of removal provides an important measurement of renal function.1 The rate-limiting factor for removal of any substance by the kidney is the renal plasma flow, an important physiological parameter. This parameter could be measured indirectly with a non-metabolized substance that is completely extracted with each circulation through the kidneys. The small aromatic compound, p-aminohippuric acid (PAH, Figure 1), approximates this ideal substance, and its clearance, termed the effective renal plasma flow (ERPF), has served as a benchmark for the indirect measurement of renal plasma flow.

Figure 1.

Figure 1

Structure and charge of agents used to evaluate effective renal plasma flow at physiological pH.

A radiopharmaceutical related to PAH, 131I-orthoiodohippuran (131I-OIH, introduced in 1960, Figure 1)2 was subsequently demonstrated to have a clearance highly correlated with PAH and an 131I-OIH/PAH clearance ratio of 87%.3 The development of 131I-OIH was a major step forward. However, the relatively long half-life (8 days) and beta emission of 131I raised the possibility of delivering a large radiation dose to patients with reduced renal function; moreover, the 364 keV gamma photon emitted by 131I was too high in energy for an optimal imaging tracer. The limitations of 131I stimulated the development of 99mTc-based tracers. 99mTc has a short half-life (6 h) and lacks beta emission, features that minimize the radiation dose to patients; in addition, 99mTc emits a 140 keV photon optimal for imaging. However, a coordination complex could not be a close structural analog of PAH.

By the late 1980s, the best of several 99mTc tracers developed for imaging the kidneys and estimating ERPF was 99mTc-mercaptoacetyltriglycine (99mTc-MAG3, Figure 1), although the clearance of 99mTc-MAG3 was only 50–65% that of 131I-OIH, making the tracer suboptimal for the estimation of ERPF.4 Nevertheless, 99mTc-MAG3 is now the most commonly used radiotracer for this purpose, even though the 99mTc-MAG3 tracer is eliminated to a small extent via the hepatobiliary tract.5 Furthermore, this undesirable hepatobiliary elimination of the 99mTc-MAG3 tracer is exacerbated in patients with impaired renal function.68

Our group has focused on the development of a 99mTc tracer that exhibits a renal clearance closer to the ERPF physiological limit. 99mTc-MAG3 has a [99mTcVO]3+ core.9 In earlier work, we employed a strategy of designing new ligands (L), chemically characterizing new ReVO(L) complexes, and evaluating the biodistribution of 99mTcVO(L) analogs.1012 The exploration of how changing L influenced 99mTcVO(L) renal clearance1018 led to a better understanding of MVO(L) chemistry and biodistribution. These efforts successfully identified two agents, 99mTc-DD-EC (ECH6 = ethylene dicysteine) and 99mTc-syn-D-MAEC (MAECH5 = mercaptoacetamide ethylene cysteine), with clearances in humans 30% higher than that of 99mTc-MAG3.1112 However, these 99mTcVO(L) agents were not sufficiently superior to 99mTc-MAG3 in human volunteers to justify patient clinical studies. The most successful ligands were tetradentate NxSy donors with dangling (not coordinated) carboxyl group(s), features also present in 99mTc-MAG3.

More recently, we changed our focus from the [99mTcVO]3+ core to the discovery of superior tracers based on the fac-[99mTcI(CO)3]+ core, but we retained the guiding principle that agents with superior clearance would likely have a carboxyl group, usually attached to a chelate ring atom or on a dangling chain terminating with the carboxyl group.12,1923 Tridentate ligands are among the best ligand types to use for preparing agents for the versatile fac-[99mTcI(CO)3]+ core.2429 NxOy donor tridentate ligands can be used with this core.22,3032 In a relatively short time, we discovered that the fac-[99mTcI(CO)3(NTA)]2− tracer [referred to here as 99mTc(CO)3(NTA), prepared from nitrilotriacetic acid (NTAH3, 1)] holds promise as a successor to 99mTc-MAG3.22,33–34 99mTc(CO)3(NTA) has a clearance rate comparable to that of 131I-OIH in rats and humans and has no observed hepatobiliary excretion.22,3334 The putative structure of 99mTc(CO)3(NTA) should differ significantly from those of PAH, 131I-OIH, and even 99mTc-MAG3 (Figure 1). Thus, for designing even better renal agents with the fac-[99mTcI(CO)3]+ core, 99mTc(CO)3(NTA) serves as a new starting point for the Re/99mTc chemistry/biodistribution strategy that we employed successfully with the [MVO]3+ core.

In this work, we explore the chemistry of fac-[ReI(CO)3(L)]n− complexes in which L are close analogs of NTA, including some L expected to form complexes having a dangling chain with an uncoordinated carboxyl group, a feature that has been considered essential for tubular transport.35 Each L has been evaluated by initial biological studies of fac-[99mTcI(CO)3(L)]n− complexes 710.3637 We report the characterization of the fac-[ReI(CO)3(NTA)]2− complex in solution and as a salt that permitted crystallographic determination of its molecular structure. Extensive comparisons of NMR data, solid-state X-ray structures, and solution behavior of fac-[ReI(CO)3(NTA)]2− and its fac-[ReI(CO)3(L)]n− analogs reported here have provided valuable insights as to why fac-[99mTcI(CO)3(NTA)]2− exhibits the observed desirable pharmacokinetic properties. Because all of these new complexes exhibit facial geometry, we commonly omit the fac- designation when discussing specific new complexes, especially in solution.

EXPERIMENTAL SECTION

Materials

Nitrilotriacetic acid (NTAH3, 1, Aldrich); N-(2-acetamido)iminodiacetic acid (ADAH2, 2) and N-(2-hydroxyethyl)iminodiacetic acid (HDAH2, 3, both from Acros Organics); and nitrilodiacetic-propionic acid (NDAPH3, 4, TCI America) were used as received. Nitrilodipropionic-acetic acid (NDPAH3, 5) was synthesized in similar yield and purity (confirmed by 1H NMR methods) by the published method.38 Nitrilotripropionic acid (NTPH3, 6, TCI America) was used as received.

General Procedures

An aqueous stock solution (0.1 M) of [Re(CO)3(H2O)3]OTf (prepared as previously reported39) was prepared and used as needed. The rhenium complexes were purified by gel filtration over Sephadex G-15 beads, eluting with deionized water at a rate of 0.5 mL/min. NMR spectra were recorded on Bruker 400 MHz spectrometers. Electrospray mass spectrometry (ESI-MS, negative mode) was performed on a Thermo Finnigan LTQ-FT instrument. HPLC analyses (monitored at 254 nm) were performed on a Waters Breeze system equipped with a Waters 2487 detector, Waters 1525 binary pump, and XTerra MS C18 column (5 μm; 4.6 × 250 mm). The HPLC gradient was composed of 0.05 M triethylammonium phosphate at pH 2.5 aqueous buffer (solvent A) and methanol (solvent B). The HPLC gradient started with 100% A from 0 to 3 min. The eluent switched at 3 min to 75% A/25% B, at 6 min to 66% A/34% B, and remained for 3 more min, followed by linear gradients: 66% A/34% B to 34% A/66% B from 9 to 20 min; and 34% A/66% B to 100% A from 20 to 30 min (flow rate of 1 mL/min).

Preparation of fac-[Re(CO)3(L)]n−

The product anionic complexes (711) formed in solution from ligands 15 are shown in the Scheme. As explained in more detail below, we use the same numbers here as for the isolated salts, which typically have the dangling carboxyl group protonated. An aqueous solution of L (15; 0.5 mmol, 5 mL) was added to a stirred solution of fac-[Re(CO)3(H2O)3]OTf (0.5 mmol, 5.0 mL) and neutralized with 1 M NaOH to maintain a pH near 6–7 throughout the reaction. A small aliquot of the reaction mixture was heated at 70 °C and monitored by HPLC until completion of the reaction; one sharp peak was observed for each complex [with RT values of 14 min (7), 10.5 min (8), 13.2 min (9), 13.8 min (10) and 14 min (11)]. For NTPH3 (6), the reaction mixture was monitored for 24 h, but no peak indicating reaction progress was observed. The reaction mixture of 6 was also heated and monitored at pH 7.5 and pH 8.5, with the same negative results as at pH 6–7.

SCHEME.

SCHEME

After the aliquots were removed, the remainder of each reaction mixture (for ligands 15) was kept at room temperature, and reaction progress was monitored by HPLC for 24 h. The reaction mixture was concentrated to 1 mL and purified by gel filtration. UV-active fractions were combined and concentrated under reduced pressure to yield fac-Re(CO)3(L). Each sample was dried to yield a white powder; 1H NMR spectra (pH 6) and HRMS data (Supporting Information) confirm that a salt with the expected fac-[Re(CO)3(L)]n− product anion (711) was isolated.

Crystal Formation

Highly purified samples of complexes 8 and 9 were dissolved in a minimal amount of water, and diluted slightly with ethanol until the solution became faintly cloudy. Solutions kept at 4 °C for several days deposited X-ray quality crystals of Na[Re(CO)3(ADA)]•2H2O (8•2H2O) and Na[Re(CO)3(HDA)]•5H2O (9•5H2O). A small sample (powder) of 7 or 10 was dissolved in 2–3 mL of water, and solid NEt4Cl (~ 30 mg) was added. Each mixture was heated for 2–3 min to obtain a clear solution and was then left undisturbed. Very small amounts of X-ray quality crystals of NEt4[Re(CO)3(NTAH)] (7) and NEt4[Re(CO)3(NDAPH)]•2H2O (10•2H2O) formed over several days. Attempts to crystallize a salt of Re(CO)3(NDPA) (11) by similar methods were unsuccessful, possibly because of its larger, more flexible, and less symmetrical structure.

Crystal Structure Determination

For complexes 710, a suitable crystal was coated with Paratone N oil, suspended in a small fiber loop, and placed in a cooled nitrogen gas stream at 173 K (7, 8, and 9) or 110 K (10) on a Bruker D8 APEX II CCD sealed tube diffractometer with graphite monochromated Mo Kα (λ = 0.71073 Å, for complexes 8 and 9) or Cu Kα (λ = 1.54178 Å, for complexes 7 and 10) radiation. Data collection, indexing, and initial cell refinements were all carried out with APEX II software.40 Frame integration and final cell refinements were conducted with SAINT software.19

Structures were solved by using direct methods and difference Fourier techniques (SHELXTL, V6.12).41 Hydrogen atoms were placed in their expected chemical positions by using the HFIX command and were included in the final cycles of least squares with isotropic Uij’s related to the atoms ridden upon. All non-hydrogen atoms were refined anisotropically. Scattering factors and anomalous dispersion corrections were taken from the International Tables for X-ray Crystallography.42 Compound 8 has four independent molecules in the asymmetric unit. The methylene groups of the tetraethylammonium cation are disordered over two positions with occupancies 0.746:0.254 in compound 10. The tetraethylammonium cation is disordered over two almost equivalent positions in compound 7. Structure solution, refinement, and generation of publication materials were performed by using SHELXL software;41 graphics were prepared by using ORTEP-3 for Windows.43

RESULTS AND DISCUSSION

In the Scheme, we illustrate the results obtained from treating fac-[Re(CO)3(H2O)3]OTf,39 the rhenium analog of the fac-[99mTc(CO)3(H2O)3]+ labeling precursor,27,44 with several aminopolycarboxylic acid ligands [NTAH3 (1), ADAH2 (2), HDAH2 (3), NDAPH3 (4), NDPAH3 (5), and NTPH3 (6)]. Ligands 15 formed complexes (711), with a metal-to-ligand ratio of 1:1 that was confirmed by analytical methods (see Supporting Information). However, NTPH3 (6) did not form a fac-[Re(CO)3(L)]n− product. This overall reaction pattern was observed in past studies in which ligands 15, but not 6, were labeled with fac-[99mTc(CO)3(H2O)3]+.37 The structures illustrated in the Scheme are consistent with our previous research on fac-M(CO)3(polyaminocarboxylate) complexes (M = Re and 99mTc),32 demonstrating that coordination of amine groups is preferred over carboxyl groups at physiological pH. The structures are also consistent with several previous solution studies on the relative ability of ligands 1 and 46 to form chelate complexes with various metal cations.4548 [Note: In the Scheme and throughout the text, we use the same number for the complex in solution or in the solid state. However, the isolated solids have the dangling carboxyl group protonated. For example, we use 7 to refer to the solid as NEt4[fac-Re(CO)3(NTAH)], but we refer to the solution species more simply as Re(CO)3(NTA). Because the charge on 7 in solution depends on pH, we do not specify its charge.]

Time courses of the reaction mixtures of ligands 16 with fac-[Re(CO)3(H2O)3]+ at pH 6–7 were monitored by HPLC at 20 °C (Supporting Information) and at 70 °C. For ligands 15, reactions were complete within 30 min at 70 °C and showed one major HPLC peak corresponding to well-defined fac-[Re(CO)3(L)]n− complexes (711). Ligands having an iminodiacetic moiety (14) formed complexes (710) that have a plane of symmetry. For 5, however, the product has one 5-membered and one 6-membered chelate ring (Scheme), and the single product HPLC peak contains a pair of enantiomers of 11. The HPLC profiles of complexes 711 were very similar to those of their 99mTc(CO)3 analogs.3637 In contrast, NTPH3 (6), which can form only 6-membered chelate rings, did not form detectable amounts of product even after prolonged heating at pH 6–7. Because one can assume that the N in NTPH3 (with three attached propionate groups) would be more basic than the N in NTAH3 (with three attached acetate groups), we evaluated 6 at a higher pH but still found the same negative result (no detectable product). Ligand 5, like 6, has three carboxyl groups, but 5 can form one 5-membered chelate ring. Ligand coordination is thus sufficiently favored by the ability to form one 5-membered chelate ring, producing adequately robust fac-[99mTc(CO)3(L)]n− agents. Even though 5 has three carboxyl groups, 2 and 3 (with two carboxyl groups) form complexes more quickly than 5. Thus, formation of the iminodiacetic tridentate chelate with two five-membered rings appears to be very favorable for facilitating formation of the tracer complexes.

X-ray Crystallography

The molecular structures of the anions in complexes 710 are shown in Figure 2, and the crystal data and details of structural refinement for these complexes are summarized in Table 1. The crystal structure of NEt4[fac-Re(CO)3(NTAH)] (7) confirmed an ONO coordination mode with two adjacent 5-membered chelate rings. Complexes formed between NTAH3 and various metal ions, including Re and Tc, have been investigated previously;22,4849 however, no crystallographically determined molecular structures of Re or Tc complexes with this ligand have been reported.

Figure 2.

Figure 2

ORTEP plots of the anions in NEt4[fac-Re(CO)3(NTAH)] (7), Na[fac-Re(CO)3(ADA)]•2H2O (8•2H2O), Na[fac-Re(CO)3(HDA)]•5H2O (9•5H2O), and NEt4[fac-Re(CO)3(NDAPH)]•2H2O (10•2H2O). Thermal ellipsoids are drawn with 50% probability.

Table 1.

Crystal Data and Structure Refinement for NEt4[fac-Re(CO)3(NTAH)] (7), Na[fac- Re(CO)3(ADA)]•2H2O (8•2H2O), Na[fac-Re(CO)3(HDA)]•5H2O (9•5H2O), and NEt4[fac-Re(CO)3(NDAPH)]•2H2O (10•2H2O)

7 8•2H2O 9•5H2O 10•2H2O
empirical formula C17H27N2O9Re C9H12N2NaO10Re C9H19N1NaO13Re C18H33N2O11Re
fw 589.6 517.4 558.44 639.66
λ (Å) 1.54178 0.71073 0.71073 1.54178
crystal system monoclinic triclinic triclinic monoclinic
space group P21/n
P1¯
P1¯
P21
a (Å) 7.6992 (9) 13.002 (4) 7.066 (2) 9.4535 (5)
b (Å) 10.5716 (11) 15.807 (5) 8.141 (3) 10.0859 (5)
c (Å) 25.726 (3) 17.133 (7) 16.647 (7) 12.7840 (7)
α (deg) 90 68.511 (6) 99.428 (6) 90
β (deg) 96.931 (4) 68.084 (4) 97.203 (6) 92.8469 (15)
γ (deg) 90 78.604 (4) 109.912 (4) 90
V3) 2078.6 (4) 3032.2 (18) 871.1 (5) 1217.41 (11)
T (K) 173 173 173 110
Z 4 8 2 2
ρ calc (mg/m3) 1.884 2.267 2.129 1.745
abs coeff (mm−1) 11.9 8.1 7.066 10.27
2θmax (deg) 68.2 26.4 29.8 68.1
R [I > 2σ(I)]a 0.037 0.024 0.026 0.016
wR2b 0.097 0.058 0.067 0.040
data/param 3585/328 12396/892 4891/226 3823/347
res. dens (eÅ−3) 2.21, −1.27 1.58, −0.99 2.59, −2.00 0.80, −0.69
Flack parameter 0.046(5)
a

R = (Σ||Fo| − |Fc||)/Σ|Fo|.

b

wR2 = [Σ[w(Fo2Fc2)2]/Σ[w(Fo2)2]]1/2, in which w = 1/[σ2(Fo2) + (dP)2 + (eP)] and P = (Fo2 + 2Fc2)/3.

Complexes 8, 9, and 10 each have an ONO coordination mode with a net negatively charged inner metal-coordination-sphere core, as does 7. The bond distances and angles of complexes 810 are also strikingly similar to those of 7, as expected (Table 2). The Re–N or Re–O bonds of ~2.2 Å are characteristically long for complexes with fac-[ReI(CO)3]+ compared to the typically shorter bond lengths of ~2.0 Å from these donor atoms to other metals or even to higher-valent Re.5051 We have noted previously that the typical non-bonded distances between 5-membered ring donor atoms are independent of such differences in M–(donor atom) bond lengths.52 The longer ReI–(donor atom) bond lengths, combined with the characteristic similarity in non-bonded separation of chelate ring donor atoms, result in the following patterns of bond angles: acute N–ReI–N or N–ReI–O chelate ring bite angles (much less than 90°), and C–ReI–N or C–ReI–O bond angles involving carbonyl carbons that are clearly less than 180° for trans angles and greater than 90° for orthogonal angles.5253 Bond angles in complexes 7 to 10 are consistent with these trends (Table 2). In addition, the dangling group extends in a practically identical manner in complexes 7, 8, and 9, but the orientation of the dangling chain is very different in 10 (Figure 2). This comparison indicates that the position of the uncoordinated dangling group may be largely independent of interactions between the chain and the [Re(CO)3(N(CH2CO2)2)] inner coordination sphere. Rather, packing forces may dictate the orientation of the longer chain in 10, where several angles that involve the N atom anchoring the dangling chain differ significantly from the corresponding angles in 7, 8, and 9 (Table 2). However, the chelate ring appears to be less sensitive to these effects, as evident from the very similar bond angles [e.g., C(6)–N(1)–C(5)] in each chelate ring of the four structurally characterized complexes.

Table 2.

Selected Bond Distances (Å) and Bond Angles (°) for NEt4[fac-Re(CO)3(NTAH)] (7), Na[fac-Re(CO)3(ADA)]•2H2O (8•2H2O), Na[fac-Re(CO)3(HDA)]•5H2O (9•5H2O), and NEt4[fac-Re(CO)3(NDAPH)]•2H2O (10•2H2O)

7 8•2H2O 9•5H2O 10•2H2O
Re–N(1) 2.266(5) 2.257(3) 2.246(3) 2.253(3)
Re–O(4) 2.124(4) 2.140(3) 2.123(3) 2.123(4)
Re–O(6) 2.111(4) 2.135(3) 2.141(3) 2.138(4)
Re–C(1) 1.920(7) 1.912(4) 1.910(4) 1.924(6)
Re–C(2) 1.908(6) 1.901(4) 1.909(4) 1.898(7)
Re–C(3) 1.913(7) 1.918(4) 1.914(4) 1.907(4)
O(4)–Re–C(1) 98.1(2) 94.83(14) 96.54(15) 95.9(2)
O(4)–Re–C(2) 173.7(2) 173.89(13) 173.57(14) 174.3(3)
O(4)–Re–C(3) 96.1(2) 96.22(14) 94.69(15) 92.7(2)
O(4)–Re–N(1) 77.16(16) 77.46(10) 78.68(11) 78.07(16)
O(4)–Re–O(6) 79.93(17) 78.40(11) 78.15(12) 79.05(18)
O(6)–Re–C(1) 175.9(2) 172.72(13) 173.57(14) 173.4(3)
O(6)–Re–C(2) 94.7(2) 97.49(14) 95.91(15) 95.2(3)
O(6)–Re–C(3) 96.4(2) 95.22(14) 96.32(14) 97.0(3)
O(6)–Re–N(1) 78.10(16) 77.65(10) 77.05(11) 76.8(2)
N(1)–Re–C(1) 98.0(2) 98.4(2) 98.5(2) 98.1(2)
N(1)–Re–C(2) 98.7(2) 97.3(2) 97.7(2) 100.3(2)
N(1)–Re–C(3) 171.9(2) 171.2(2) 171.4(2) 169.6(2)
C(6)–N(1)–C(5) 111.2(5) 109.4(3) 110.0(3) 108.9(3)
C(8)–N(1)–Re 110.3(4) 113.4(2) 112.7(2) 117.9(2)

In summary, crystallography confirms that the structures of 710 are consistent with previous reports;31,5455 the inner coordination sphere structures of 8 and 9 do not differ from that of 7 and are not influenced by the nature of the dangling chains. Because attempts to crystallize 11 were not successful, comparisons between 7 and 11 must rely on the NMR and solution studies described below.

NMR Spectroscopy

Bond lengths and angles are sometimes insensitive to changes in electron richness within the chelate rings, but 13C NMR chemical shift data can provide useful insight concerning both electron richness and structure. Complexes 711 were characterized by 1H and 13C NMR spectroscopy in D2O; selected data appear in Table 3, and complete data are listed in Supporting Information). Table 4 lists 1H and 13C NMR shifts at high (~7.5–8.5) and low (~2.0–2.5) pH values for 15 mM solutions of 7, 10, and 11 in D2O. The 1H and 13C NMR shifts for complexes 8 and 9 were not significantly altered when the pH was changed from high (~7.5–8.5) to low (~2.0–2.5) pH (cf. Tables S1 and S2 in Supporting Information).

Table 3.

1H and 13C NMR Shifts (ppm) of the 5-membered Chelate Rings in Complexes 7–11 (15 mM in D2O, 25 °C) at Near Neutral pH (pH Values in Parentheses at Column Top)

7 8 9 10 11
signal/(pH) (8.40) (7.23) (7.45) (7.74) (7.50)
1H NMR shifts
–N–CH2 exo-CH 4.06 4.04 4.03 3.91 3.85
–N–CH2 endo-CH 3.95 3.98 3.76 3.62 3.71
13C NMR shifts
–N–CH2 66.21 66.29 65.89 65.06 64.03
–CO2 186.80 186.10 186.20 186.05 186.27

Table 4.

1H and 13C NMR Shifts (ppm) of Re(CO)3(NTA) (7), Re(CO)3(NDAP) (10), and Re(CO)3(NDPA) (11) (15 mM in D2O, 25 °C) at High and Low pH (Values in Parentheses at Top of Columns)

7 10 11
signal/(pH) (8.40) (2.46) (7.74) (2.16) (7.50) (2.47)
1H NMR shifts
–N–CH2 dangling 4.08   4.27   3.70   3.75   3.74   3.78  
–C–CH2 dangling 2.63   2.86   2.62   2.87  
2.55   2.79  
13C NMR shifts
–N–CH2 dangling 73.35 70.99 69.01 67.00 65.08 63.17
–C–CH2 dangling 36.21 32.95 35.39 32.14

NMR signals were assigned by analyzing the splitting pattern, integration, and data from 2D NMR experiments. Following our previous convention for fac-[Re(CO)3L]n complexes,52,56 we designate the magnetically distinct ring CH2 protons in 7 as endo-H or exo-H, according to their orientation either toward (endo) or away (exo) from the carbonyl ligands (Figure 3). The most extensive studies were performed on Re(CO)3(NTA) (7), both because it is the analog of the promising 99mTc renal agent and because it is a prototype for assigning signals for 8, 9, and 10. Re(CO)3(NDPA) (11) was also studied extensively because its chemical behavior under strongly acidic and basic conditions is quite different from that of 7. To explain these differences, we also conducted detailed NMR experiments to assign signals for 11.

Figure 3.

Figure 3

Anion of NEt4[fac-Re(CO)3(NTAH)] (7) showing the designation of endo- and exo-CH protons of the methylene group in the 5-membered chelate rings.

1H and 13C NMR Assignments for Re(CO)3(NTA) (7)

The 1H NMR spectrum of 7 at pH = 8.40 (Supporting Information) shows a singlet integrating to two protons and an AB pattern; the two AB “doublets” each integrated to two protons. The two equivalent 5-membered chelate rings in 7 create a magnetically equivalent environment for the protons of the dangling –CH2CO2 moiety, thus allowing the unambiguous assignment of the singlet at 4.08 ppm to that moiety. The singlet for the dangling –CH2CO2H group moved downfield as the pH of the solution was lowered (Table 4). A plot of the chemical shift of this singlet versus pH shows a typical sigmoid curve (Figure 4). Chemical shift changes observed for other peaks were insignificant. This singlet for 7 has an HSQC cross-peak to a 13C NMR signal at 73.35 ppm, thus assigning it to the CH2 group of the dangling –CH2CO2 moiety. Furthermore, the HSQC cross-peaks from the two AB “doublets” to a 13C NMR signal at 66.21 ppm allow the assignment of the signals to the equivalent methylene groups in the chelate rings.

Figure 4.

Figure 4

Variation with pH of the chemical shift (ppm) of the 1H NMR signal arising from the dangling CH2 group of Re(CO)3(NTA) (7) (15 mM) in D2O at 25 °C.

In the ROESY spectrum for 7 (at pH ~2.5, Supporting Information), the CH2 singlet (4.27 ppm) of the dangling –CH2CO2H chain has strong and weak NOE cross-peaks, respectively, to the 3.96 and 4.03 ppm signals of the AB doublets arising from the–CH2CO2 protons of the chelate rings. The shorter average non-bonded distances from the dangling group protons to the endo-CH protons (2.29 Å) than to the exo-CH protons (3.26 Å) assigns the 3.96 and 4.03 ppm AB doublets to the endo-CH and exo-CH protons, respectively.

1H and 13C NMR Assignments for Re(CO)3(ADA) (8), Re(CO)3(HDA) (9) and Re(CO)3(NDAP) (10)

After the pH was lowered to 2, the shifts of the 1H and 13C NMR signals of 8 and 9 showed no significant change, as expected (Supporting Information). However, the two multiplets of the methylene groups of the dangling –CH2CH2CO2 moiety of 10 clearly shifted downfield, with the expected protonation of the carboxyl group at pH 2.16 (Table 4). The greater shift change for the upfield multiplet (~0.24 ppm) than for the downfield multiplet (~0.05 ppm) allowed the assignment of the upfield multiplet (~2.63 ppm at pH ~7.5) to the –CH2CO2 group, and the downfield multiplet (~3.70 ppm at pH ~7.5) to the N–CH2 group of the dangling –CH2CH2CO2 moiety. The 13C NMR signals of these methylene groups were assigned from HSQC spectra at the two different pH values (Supporting Information).

1H and 13C NMR Assignments for Re(CO)3(NDPA) (11)

In the spectrum of 11 at pH 7.50 (Figure 5), the clear AB 1H NMR doublet at 3.85 ppm and the AB doublet at 3.71 ppm (overlapped with a multiplet) have an HSQC cross-peak with the 13C NMR signal at 64.03 ppm. These AB doublets have COSY cross-peaks (strong) only with each other. Consequently, these signals can all be unambiguously assigned to the methylene group of the 5-membered chelate ring. All other CH 1H NMR signals arise from the two CH2CH2 moieties, and these assignments, as well as other 13C NMR assignments described and summarized in Supporting Information.

Figure 5.

Figure 5

1H NMR spectrum of Re(CO)3(NDPA) (11) in D2O (pH 7.50) at 25 °C. The exo-CH and endo-CH signals of the 5-membered chelate ring are labeled. The (6) label denotes CH multiplets from the 6-membered ring.

Ligand Challenge Reactions and the Effect of Acid and Base on Re(CO)3(NTA) (7) and Re(CO)3(NDPA) (11)

The 1H NMR signals of 7 in D2O (15 mM, pH 8.40) showed no change, even after several weeks. After the pH of this solution of 7 was lowered to 2.46, no changes were observed in the 1H NMR spectrum even after 14 days. Challenge reactions were carried out on solutions of 7 (5 mM) in D2O by adding a fivefold molar ratio of potentially coordinating ligands. Moderately basic ligands [histidine, cysteine, or 4-methylimidazole, giving respective pH values of 8.2, 7.4, and 9.2] and highly basic ligands [isopropylamine, diethylenetriamine (dien), and dimethylaminopyridine, in solutions at pH 7] did not alter the 1H NMR signals for 7 even after two weeks.

A 5 mM solution of 11 in D2O (pH 7.59) was stable for two months. When a fivefold molar ratio of histidine was added to this solution, the pH of the solution changed to ~7.9, but no changes were observed in the 1H NMR signals for 11 after two weeks. The spectrum of another solution of 11 in D2O (15 mM) was recorded at 7.50 and then at pH 2.47. Some 1H NMR signals had shifted in the first spectrum recorded (at 15 min) for the pH 2.47 solution (Supporting Information). Very small 1H NMR signals corresponding to the free NDPAH3 ligand were also observed at 15 min. These signals gradually grew with time. At 10 days, the intensity of the signals indicated that ~26% of 11 decomposed to form free NDPAH3.

Without pH control, addition of the three highly basic ligands with 7 and of dien with 11 increased the solution pH to ~11–12. The original methylene signals for the five-membered chelate rings for both 7 and 11 decreased owing to H to D exchange, consistent with the slight acidity of such methylene protons.57 Spectral changes occurred more rapidly with 7 than with 11. The 1H NMR spectra for 7 in all three cases showed very similar peaks for an unidentified decomposition product, suggesting that these changes were caused by the high basicity of the solutions and not by any direct effect of the basic amines on 7. Adding a fivefold molar ratio of sodium hydroxide to 11 (5 mM) in D2O increased the pH of the solution to ~12.5. After one day, the 5-membered chelate ring methylene 1H NMR signals for 11 were detectable as a result of H to D exchange and decomposition. When the pH was lowered, the signals indicating decomposition were identified as being from free NDPAH3. Both observations (slower H to D exchange and longer decomposition times for 11 than for 7) are indicative of a more electron-rich metal center in 11 than in 7. In summary, Re(CO)3(NDPA) (11) is robust under neutral conditions but decomposes under strongly acidic or highly basic conditions. In contrast, Re(CO)3(NTA) (7) decomposes under strongly basic conditions about twice as fast as 11 but is robust from highly acidic to slightly basic conditions.

Relationship of the Acid and Base Sensitivity of 7 and 11 to Structure and to the Electronic Nature of the Chelate Rings

To explore other possible reasons for these differences in the effects of acid and base on complexes 7 and 11, we compared the shifts of the corresponding N–CH2 13C NMR signals of the dangling group and the 5-membered chelate rings of these complexes (Tables 3 and 4).

For pH conditions at which the dangling group is monoanionic (~7.5–8.5), the N–CH2 13C NMR signal of the dangling moiety is 8.27 ppm more upfield for 11 than for 7. Also, the N–CH2 13C NMR signal of the 5-membered chelate ring in 11 is 2.18 ppm more upfield than for 7. This upfield shift indicates that the ReI center is more electron rich in 11 than in 7, and therefore the CH2 group of the 5-membered chelate ring of 11 is less prone to deprotonation by base at high pH than are the CH2 groups in the 5-membered rings of 7. This finding is consistent with the H to D exchange just mentioned above because deprotonation of the methylene group is the first step in the H to D exchange process.57 However, the electron richness of the ReI center of 11 will make the carboxyl end of the six-membered ring more prone to dissociation. We expect that an undetectably low amount of the ring-opened form of 11 exists. At low pH, protonation of the dissociated carboxyl group should increase the abundance of this undetectable open form, and the greater abundance would lead to the eventual dissociation of more donor groups and to the release of the free NDPAH3 ligand, explaining the observation of the NDPAH3 signals in low pH solutions of 11. When complex 7 was treated with acid, no changes in the 1H NMR signals of 7 were observed, nor were NTAH3 signals observed. This robustness of 7 toward acid undoubtedly arises from two of its properties: the ReI center is less electron rich in 7 than in 11, and both chelate rings in 7 are favorable 5-membered chelate rings. Both of these properties of 7 reduce the amount of chelate ring opening that leads to decomposition.

Relationship of Structure, Charge, and the Electronic Nature of the Chelate Rings to Biodistribution

The atoms of fac-[MI(CO)3(L)]n− anions that are most likely to influence biodistribution are those exposed to solvent and thus accessible for interactions with proteins and receptors. These atoms can be grouped into three zones (Figure 6). The three facially coordinated carbonyl ligands constitute ZONE 1. This “constant” zone is very similar for all complexes and thus will not be a significant source of the observed variation in biodistribution as the chelate ligand is changed. ZONE 2 consists of the CH2CO2 or CH2CH2CO2 components of the chelate rings, except for the N–CH2 endo-CH protons. ZONE 3 consists of the “variable” dangling chain and the endo-CH protons of the chelate ring N–CH2 groups. To evaluate the relative influence of ZONE 2 and ZONE 3 on biodistribution, we begin by assessing the electronic nature of ZONE 2 in 7, 8, and 9; these complexes have very similar structures, differing only in the dangling chain (Figure 2).

Figure 6.

Figure 6

Side view of Re(CO)3(NTA) (7), showing the “constant” ZONE 1 (green), the “solvent-exposed chelate ring” ZONE 2 (rose), and the “variable dangling-chain” ZONE 3 (blue). The figure shows the location of the exo-CH protons in ZONE 2 and the endo-CH protons in ZONE 3.

A dangling chain could influence the NMR shifts of a proton by such factors as a through-space anisotropic effect, an alteration of the solvation sphere, or a through-bond inductive effect. Only the latter factor is likely to influence the shifts of atoms that are spatially remote from the dangling chain. The 5-membered-ring exo-CH protons and carbon atoms are relatively far from the dangling chain; thus, the shifts of the NMR signals of these atoms should only be sensitive to through-bond inductive effects. The shifts of the exo-CH 1H NMR signals of complexes 7, 8, and 9 are very similar (Table 3), as are the shifts of the 5-membered ring 13C NMR signals (Table 4). Thus, although 7 has a dinegative charge and 8 and 9 are mononegative, both types of ZONE 2 signals (the exo-CH 1H NMR and chelate ring 13C NMR signals) indicate that ZONE 2 has very similar electronic properties in 7, 8, and 9. The dangling chains in these complexes appear to affect the electronic properties of the [Re(CO)3(N(CH2CO2)2)] moiety in a very similar manner. However, the 13C NMR data for Re(CO)3(NDAP) (10) are consistent with a small but clear effect of the –CH2CH2CO2 dangling chain on the electronic properties of this moiety.

ZONE 3 differs, of course, in the nature of the dangling chain of 7, 8, and 9. The endo-CH protons are in ZONE 3 and are positioned close to the dangling chain. As expected from this proximity, the 1H NMR shift of the endo-CH signal for 9 does differ from those of the endo-CH signal for 7 and 8, which are quite similar to each other (Table 3).

Despite lacking a negatively charged pendant carboxyl group and having a low monoanionic charge, the 99mTc analogs of 8 and 9, 99mTcI(CO)3(ADA) and 99mTcI(CO)3(HDA), each exhibit a rapid renal extraction rate, practically identical to that of 99mTc(CO)3(NTA).36 Therefore, the negative charge of the dangling acetate group of 99mTc(CO)3(NTA) (the 99mTc analog of 7) has no identifiable effect on the renal extraction of that agent via the tubules. Furthermore, the many points of similarity in the structures and the electronic properties of ZONE 2 of the [Re(CO)3(N(CH2CO2)2)] moiety in complexes 7, 8, and 9 lead us to conclude that the primary factor responsible for the favorable pharmacokinetic properties of their 99mTc analogs resides chiefly within ZONE 2 of the [99mTcI(CO)3(N(CH2CO2)2)] moiety and much less so in the dangling group. In previous studies of 99mTc renal agents spanning decades, an uncoordinated negative carboxyl group (often in a dangling chain) appeared to be the key factor favoring a high rate of renal extraction.12,21,35

Compounds 7, 10, and 11 all contain such a negatively charged dangling chain with a terminal carboxyl group characteristically associated with a high rate of renal excretion in fac-99mTcI(CO)3(L) agents. Nevertheless, 99mTcI(CO)3(NDAP) and 99mTcI(CO)3(NDPA), the respective fac-99mTcI(CO)3(L) analogs of 10 and 11, exhibited a significantly reduced rate of renal excretion compared to 99mTcI(CO)3(NTA).37 For example, urine activities (as % of that of 131I-OIH, which was used as an internal control) at 10 min were 77% for 99mTcI(CO)3(NDAP) and 64% for 99mTcI(CO)3(NDPA), versus 108% for 99mTcI(CO)3(NTA).37 It may well be that electron donation from the dangling group into the [99mTcI(CO)3(N(CH2CO2)2)] moiety, as indicated clearly by 13C NMR data for 10, more than offsets the effect of the negative carboxyl-bearing dangling group. (The 13C NMR shifts of the 5-membered ring CH2 signal of 10 and 11 are respectively ~1 and 2 ppm further upfield than the relatively similar shifts for this signal in the spectra of 7, 8, and 9.) Alternatively or possibly in combination with the electron-donating inductive effect on ZONE 2, the larger size and greater lipophilicity of the 6-membered chelate ring (such as in 11) and of the dangling groups (such as in 10 and 11) are responsible for the significant decrease in clearance of fac-99mTcI(CO)3(L) analogs of 10 and 11.

SUMMARY AND CONCLUSIONS

We have crystallized and structurally characterized for the first time a fac-M(CO)3(NTA) complex, NEt4[fac-Re(CO)3(NTAH)], along with a number of related complexes with aminopolycarboxylate ligands. In addition, the crystallographically determined structure of NEt4[fac-Re(CO)3(NTAH)] provides compelling evidence that the structure of the promising 99mTc(CO)3(NTA) renal tracer currently undergoing evaluation in patients contains the expected symmetrical ONO coordination mode with two adjacent 5-membered chelate rings.

The reaction progress with the NDPAH3 (5) and NTPH3 (6) ligands reflects the relative difficulty of forming 6-membered chelate rings. [Re(CO)3(NDPA)]2− (11) formed more slowly than complexes 710, which have exclusively 5-membered rings. Furthermore, the attempt to make [Re(CO)3(NTP)]2− by using 6, a ligand which can form only six-membered chelate rings, was not successful (Scheme), even after prolonged heating, a result exactly analogous to that obtained in 99mTc labeling studies with 6.37 At physiologically relevant pH, neither 7 nor 11 decomposed detectably, nor did they undergo ligand exchange; thus, ONO coordination with two 5-membered chelate rings or one 5- and one 6-membered chelate ring provides sufficient robustness. The decomposition of 11 in acidic solution is attributed to a facile opening of its 6-membered chelate ring. In highly basic solution, 11 decomposed more slowly than 7, a result suggesting that deprotonation of a CH in a 5-membered chelate ring initiates decomposition.

The structural details and NMR data we report for complexes 7, 8, and 9 indicate that the structural features and the electronic properties of the solvent-exposed atoms in the [Re(CO)3(N(CH2CO2)2)] moiety and projecting away from the dangling chain are very similar, despite the fact that the dangling groups in 7, 8, and 9 (CH2CO2, CH2CONH2, and CH2CH2OH, respectively) differ in charge and other ways. In turn, these findings very strongly indicate that the similar pharmacokinetic properties reported for the 99mTc analogs of 7, 8, and 9, 99mTcI(CO)3(NTA), 99mTcI(CO)3(ADA) and 99mTcI(CO)3(HDA), all with dangling groups of comparable size, are determined primarily by the features of the solvent-exposed atoms of the [99mTc(CO)3(N(CH2CO2)2)] moiety itself, rather than by the charge of the dangling group or the presence of a carboxyl group in the dangling chain. This conclusion is also in agreement with our previous results with the 99mTc(CO)3(UEDDA) agent [UEDDAH2 = unsymmetrical ethylenediamine-N,N-diacetic acid, a ligand with two CH2CO2 chains on one ethylenediamine nitrogen]. At physiological pH, 99mTc(CO)3(UEDDA) has a dangling chain with an uncoordinated carboxyl group but an NNO donor set rather than the ONO iminodiacetate moiety. Hepatobiliary excretion and intestinal secretion of 99mTc(CO)3(UEDDA) were higher compared to the mononegative 99mTc agents, 99mTc(CO)3(ADA) and 99mTc(CO)3(HDA), both of which have no uncoordinated carboxyl groups.32,37

Our interpretation that the inner-sphere ligand properties can dominate over the dangling chain properties is a departure from concepts developed in investigations employing the Re/99mTc strategy to develop fac-[99mTcI(CO)3L]n− and 99mTcVO(L) agents reported over several decades. The information gained here into the effects of the dangling group on the structural and electronic properties of the [99mTc(CO)3(N(CH2CO2)2)] moiety from the study of fac-[Re(CO)3(L)]n− complexes provides a new perspective on the potential roles of the inner-sphere chelate ring atoms and of the dangling chain.

Supplementary Material

Supplemental

SYNOPSIS.

The formation and stability of several fac-[ReI(CO)3(L)]n− complexes were examined, and their structures were thoroughly characterized, resulting in the first reported crystal structure of fac-[ReI(CO)3(NTA)]2−. These characterizations were used to examine the structure-activity relationship between a promising radiopharmaceutical, fac-[99mTcI(CO)3(NTA)]2−, and its pharmacokinetic properties. Specifically, we demonstrated that the relative contribution of the [99mTcI(CO)3(N(CH2CO2)2)] moiety to the renal clearance and low hepatobiliary uptake of fac-[99mTcI(CO)3(L)]n− analogs is more significant than previously thought.

Acknowledgments

This work was supported by the National Institute of Health/National Institute of Diabetes and Digestive and Kidney Diseases (Grant No. R37 DK038842). The authors thank Drs. John Bacsa and Kenneth Hardcastle at Emory for discussions regarding crystal preparation and X-ray structure determination. We also thank Dr. Svetlana Pakhomova for final refinements of the molecular structures and for preparing tables, files, and figures of 7, 8, 9 and 10. L.G.M. thanks the RAYMOND F. SCHINAZI INTERNATIONAL EXCHANGE PROGRAMME between the University of Bath, U.K., and Emory University, Atlanta, GA, U.S.A. for a Faculty Fellowship. We also thank Dr. Patricia A. Marzilli for her invaluable comments during the preparation of the manuscript.

Footnotes

Supporting Information. Additional experimental details for complexes 711, including yields, 1H NMR spectral data, and HRMS data; additional details of the NMR signal assignments for 11; tables of 1H and 13C NMR shifts of complexes 711 in D2O at high and low pH and 25 °C; 1H NMR spectra of 7, 10, and 11, showing exo- and endo-CH signals of the 5-membered chelate rings and the N-CH2 of the dangling chain; ROESY spectrum of 7 at pH ~ 2.5 in D2O at 25 °C; 1H NMR spectra of 11 in D2O at 25 °C, showing decomposition under acidic conditions; figure showing the time dependence for the formation of products by ligands 15; and CIF files detailing the crystal structures for 710. This material is available free of charge from the Internet at http://pubs.acs.org.

Notes

The authors declare no competing financial interest.

References

  • 1.Taylor A, Schuster D, Alazraki N. A Clinician’s Guide to Nuclear Medicine. Society of Nuclear Medicine; Reston, VA: 2006. pp. 45–74. [Google Scholar]
  • 2.Tubis M, Posnick E, Nordyke RA. Exp Biol Med. 1960;103:497–498. doi: 10.3181/00379727-103-25571. [DOI] [PubMed] [Google Scholar]
  • 3.Burbank M, Tauxe W, Maher F, Hunt J. Mayo Clin Proc. 1961;36 [PubMed] [Google Scholar]
  • 4.Eshima D, Taylor A., Jr Semin Nucl Med. 1992;22:61–73. doi: 10.1016/s0001-2998(05)80082-0. [DOI] [PubMed] [Google Scholar]
  • 5.Shattuck L, Eshima D, Taylor AT, Anderson TL, Graham DL, Latino FA, Payne SE. J Nucl Med. 1994;35:349–355. [PubMed] [Google Scholar]
  • 6.Sanchez J, Freidman S, Kempf J, Abdel-Dayem H. Clin Nucl Med. 1993;18:30–34. doi: 10.1097/00003072-199301000-00007. [DOI] [PubMed] [Google Scholar]
  • 7.Rosen J. Clin Nucl Med. 1993;18:713–714. doi: 10.1097/00003072-199308000-00020. [DOI] [PubMed] [Google Scholar]
  • 8.Taylor A, Jr, Eshima D, Christian P, Wotten W, Hansen L, McElvany K. J Nucl Med. 1988;29:616–622. [PubMed] [Google Scholar]
  • 9.Hansen L, Taylor AT, Marzilli LG. Met -Based Drugs. 1995;2:105–110. doi: 10.1155/MBD.1995.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Lipowska M, Hayes BL, Hansen L, Taylor A, Marzilli LG. Inorg Chem. 1996;35:4227–4231. doi: 10.1021/ic9514657. [DOI] [PubMed] [Google Scholar]
  • 11.Taylor A, Hansen L, Eshima D, Malveaux E, Folks R, Shattuck L, Lipowska M, Marzilli LG. J Nucl Med. 1997;38:821–826. [PubMed] [Google Scholar]
  • 12.Taylor AT, Lipowska M, Hansen L, Malveaux E, Marzilli LG. J Nucl Med. 2004;45:885–891. [PubMed] [Google Scholar]
  • 13.Hansen L, Marzilli LG, Eshima D, Malveaux EJ, Folks R, Taylor A., Jr J Nucl Med. 1994;35:1198–205. [PubMed] [Google Scholar]
  • 14.Hansen L, Cini R, Taylor A, Marzilli LG. Inorg Chem. 1992;31:2801–2808. [Google Scholar]
  • 15.Marzilli LG, Banaszczyk MG, Hansen L, Kuklenyik Z, Cini R, Taylor A., Jr Inorg Chem. 1994;33:4850–4860. [Google Scholar]
  • 16.Hansen L, Lipowska M, Meléndez E, Xu X, Hirota S, Taylor AT, Marzilli LG. Inorg Chem. 1999;38:5351–5358. [Google Scholar]
  • 17.Hansen L, Hirota S, Xu X, Taylor AT, Marzilli LG. Inorg Chem. 2000;39:5731–5740. doi: 10.1021/ic000183q. [DOI] [PubMed] [Google Scholar]
  • 18.Lipowska M, Hansen L, Xu X, Marzilli PA, Taylor A, Marzilli LG. Inorg Chem. 2002;41:3032–3041. doi: 10.1021/ic011325z. [DOI] [PubMed] [Google Scholar]
  • 19.Lipowska M, Hansen L, Marzilli LG, Taylor AT. J Nucl Med. 2001;42:S259. [PubMed] [Google Scholar]
  • 20.He H, Lipowska M, Christoforou AM, Marzilli LG, Taylor AT. Nucl Med Biol. 2007;34:709–716. doi: 10.1016/j.nucmedbio.2007.06.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Nosco DL, Beaty-Nosco JA. Coord Chem Rev. 1999;184:91–123. [Google Scholar]
  • 22.Lipowksa M, Marzilli LG, Taylor AT. J Nucl Med. 2009;50:454–460. doi: 10.2967/jnumed.108.058768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Lipowska M, Klenc J, Marzilli LG, Taylor AT. J Nucl Med. 2012;53:1277–1283. doi: 10.2967/jnumed.111.102236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Banerjee SR, Maresca KP, Francesconi L, Valliant J, Babich JW, Zubieta J. Nucl Med Biol. 2005;32:1–20. doi: 10.1016/j.nucmedbio.2004.09.001. [DOI] [PubMed] [Google Scholar]
  • 25.Schibli R, Schubiger AP. Eur J Nucl Med. 2002;29:1529–1542. doi: 10.1007/s00259-002-0900-8. [DOI] [PubMed] [Google Scholar]
  • 26.Alberto R, Schibli R, Waibel R, Abram U, Schubiger AP. Coord Chem Rev. 1999;190–192:901–919. [Google Scholar]
  • 27.Alberto R, Schibli R, Egli A, Schubiger AP, Abram U, Kaden TA. J Am Chem Soc. 1998;120:7987–7988. doi: 10.1021/ic980112f. [DOI] [PubMed] [Google Scholar]
  • 28.Schibli R, La Bella R, Alberto R, Garcia-Garayoa E, Ortner K, Abram U, Schubiger PA. Bioconjugate Chem. 2000;11:345–351. doi: 10.1021/bc990127h. [DOI] [PubMed] [Google Scholar]
  • 29.Shen Y, Schottelius M, Zelenka K, De Simone M, Pohle K, Kessler H, Wester H-J, Schmutz P, Alberto R. Bioconjugate Chem. 2012;24:26–35. doi: 10.1021/bc3003327. [DOI] [PubMed] [Google Scholar]
  • 30.Alberto R, Bugaj JE, Dyszlewski M. WO 2001/000637. 2001 Jan 4;A1 [Google Scholar]
  • 31.Klenc J, Lipowska M, Taylor AT, Marzilli LG. Eur J Inorg Chem. 2012;2012:4334–4341. doi: 10.1002/ejic.201200599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Lipowska M, He H, Xu X, Taylor AT, Marzilli PA, Marzilli LG. Inorg Chem. 2010;49:3141–3151. doi: 10.1021/ic9017568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Taylor AT, Lipowska M, Cai H. J Nucl Med. 2013;54:578–84. doi: 10.2967/jnumed.112.108357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Taylor AT, Lipowska M, Marzilli LG. J Nucl Med. 2010;51:391–396. doi: 10.2967/jnumed.109.070813. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Shikano N, Kanai Y, Kawai K, Ishikawa N, Endou H. J Nucl Med. 2004;45:80–85. [PubMed] [Google Scholar]
  • 36.Lipowska M, Klenc J, Taylor A. J Nucl Med. 2014;55:S1206. [Google Scholar]
  • 37.Lipowska M, Taylor AT, Marzilli LG. In: Technetium and Other Radiometals in Chemistry and Medicine. Mazzi U, Eckelman WC, Volkert WA, editors. SGEditoriali; Padova: 2010. pp. 281–284. [Google Scholar]
  • 38.Murugesu M, Clérac R, Pilawa B, Mandel A, Anson CE, Powell AK. Inorg Chim Acta. 2002;337:328–336. [Google Scholar]
  • 39.He H, Lipowska M, Xu X, Taylor AT, Carlone M, Marzilli LG. Inorg Chem. 2005;44:5437–5446. doi: 10.1021/ic0501869. [DOI] [PubMed] [Google Scholar]
  • 40.Bruker APEX2. 6.45A. Bruker AXS Inc; Madison, Wisconsin USA: 2007. [Google Scholar]
  • 41.Sheldrick GM. Acta Crystallogr. 2008;A64:112–122. doi: 10.1107/S0108767307043930. [DOI] [PubMed] [Google Scholar]
  • 42.Wilson AJC. International Tables for X-ray Crystallography. C Academic Publishers; Dordrecht: 1992. [Google Scholar]
  • 43.Farrugia L. J Appl Crystallogr. 1997;30:565. [Google Scholar]
  • 44.Alberto R, Ortner K, Wheatley N, Schibli R, Schubiger AP. J Am Chem Soc. 2001;123:3135–3136. doi: 10.1021/ja003932b. [DOI] [PubMed] [Google Scholar]
  • 45.Chaberek S, Martell AE. J Am Chem Soc. 1953;75:2888–2892. [Google Scholar]
  • 46.Mederos A, Domínguez S, Medina AM, Brito F, Chinea E, Bazdikian K. Polyhedron. 1987;6:1365–1373. [Google Scholar]
  • 47.Araujo ML, Brito F, Cecarello I, Guilarte C, Martinez JD, Monsalve G, Oliveri V, Rodriguez I, Salazar A. J Coord Chem. 2008;62:75–81. [Google Scholar]
  • 48.Lipowska M, Taylor A, Marzilli LG. Nucl Med Biol. 2010;37:697–698. [Google Scholar]
  • 49.Marti N, Spingler B, Breher F, Schibli R. Inorg Chem. 2005;44:6082–6091. doi: 10.1021/ic050442h. [DOI] [PubMed] [Google Scholar]
  • 50.Britten JF, Lock CJL, Pratt WMC. Acta Crystallogr. 1982;B38:2148–2155. [Google Scholar]
  • 51.Maheshwari V, Carlone M, Fronczek FR, Marzilli LG. Acta Crystallogr. 2007;B63:603–611. doi: 10.1107/S0108768107027024. [DOI] [PubMed] [Google Scholar]
  • 52.Christoforou AM, Marzilli PA, Fronczek FR, Marzilli LG. Inorg Chem. 2007;46:11173–11182. doi: 10.1021/ic701576u. [DOI] [PubMed] [Google Scholar]
  • 53.Perera T, Marzilli PA, Fronczek FR, Marzilli LG. Inorg Chem. 2010;49:2123–2131. doi: 10.1021/ic901705x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Lipowska M, Cini R, Tamasi G, Xu X, Taylor AT, Marzilli LG. Inorg Chem. 2004;43:7774–7783. doi: 10.1021/ic049544i. [DOI] [PubMed] [Google Scholar]
  • 55.He H, Lipowska M, Xu X, Taylor AT, Marzilli LG. Inorg Chem. 2007;46:3385–3394. doi: 10.1021/ic0619299. [DOI] [PubMed] [Google Scholar]
  • 56.Perera T, Marzilli PA, Fronczek FR, Marzilli LG. Inorg Chem. 2010;49:5560–5572. doi: 10.1021/ic100386c. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Buckingham DA, Marzilli LG, Sargeson AM. J Am Chem Soc. 1967;89:3428–3433. doi: 10.1021/ja00993a061. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental

RESOURCES